Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Lorentzen CL"'
Autor:
Lorentzen CL; Department of Oncology, CCIT-DK, Herlev, Denmark., Kjeldsen JW; Department of Oncology, CCIT-DK, Herlev, Denmark., Ehrnrooth E; IO Biotech ApS, Copenhagen, Denmark., Andersen MH; Department of Oncology, CCIT-DK, Herlev, Denmark., Marie Svane I; Department of Oncology, CCIT-DK, Herlev, Denmark Inge.Marie.Svane@regionh.dk.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2023 May; Vol. 11 (5).
Autor:
Mørk SK; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Kongsted P; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Westergaard MCW; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Albieri B; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Granhøj JS; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Donia M; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Martinenaite E; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.; IO Biotech Aps, Copenhagen, Denmark., Holmström MO; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Madsen K; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Kverneland AH; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Kjeldsen JW; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Holmstroem RB; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Lorentzen CL; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Nørgaard N; Department of Urology, Copenhagen University Hospital, Herlev, Denmark., Andreasen LV; Statens Serum Institut, Center for Vaccine Research, Copenhagen, Denmark., Wood GK; Statens Serum Institut, Center for Vaccine Research, Copenhagen, Denmark., Christensen D; Statens Serum Institut, Center for Vaccine Research, Copenhagen, Denmark., Klausen MS; EVAXION BIOTECH A/S, Hørsholm, Denmark., Hadrup SR; Department of Health Technology, Technical University of Denmark (DTU), HEALTH TECH, Kongens Lyngby, Denmark., Thor Straten P; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Andersen MH; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Svane IM; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
Publikováno v:
Frontiers in immunology [Front Immunol] 2023 Mar 14; Vol. 14, pp. 1122977. Date of Electronic Publication: 2023 Mar 14 (Print Publication: 2023).
Autor:
Lorentzen CL; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Martinenaite E; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; IO Biotech ApS, Copenhagen, Denmark., Kjeldsen JW; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Holmstroem RB; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Mørk SK; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Pedersen AW; IO Biotech ApS, Copenhagen, Denmark., Ehrnrooth E; IO Biotech ApS, Copenhagen, Denmark., Andersen MH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Publikováno v:
Frontiers in immunology [Front Immunol] 2022 Oct 17; Vol. 13, pp. 1023023. Date of Electronic Publication: 2022 Oct 17 (Print Publication: 2022).
Autor:
Lorentzen CL; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Haanen JB; Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Met Ö; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Svane IM; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. Electronic address: inge.marie.svane@regionh.dk.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2022 Oct; Vol. 23 (10), pp. e450-e458.
Autor:
Kjeldsen JW; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Lorentzen CL; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Martinenaite E; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; IO Biotech Aps, Copenhagen, Denmark., Ellebaek E; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Donia M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Holmstroem RB; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Klausen TW; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Madsen CO; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Ahmed SM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Weis-Banke SE; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Holmström MO; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Hendel HW; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Herlev, Denmark., Ehrnrooth E; IO Biotech Aps, Copenhagen, Denmark., Zocca MB; IO Biotech Aps, Copenhagen, Denmark., Pedersen AW; IO Biotech Aps, Copenhagen, Denmark., Andersen MH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. inge.marie.svane@regionh.dk.
Publikováno v:
Nature medicine [Nat Med] 2022 Apr; Vol. 28 (4), pp. 871.
Autor:
Kjeldsen JW; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Lorentzen CL; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Martinenaite E; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; IO Biotech Aps, Copenhagen, Denmark., Ellebaek E; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Donia M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Holmstroem RB; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Klausen TW; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Madsen CO; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Ahmed SM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Weis-Banke SE; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Holmström MO; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Hendel HW; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Herlev, Denmark., Ehrnrooth E; IO Biotech Aps, Copenhagen, Denmark., Zocca MB; IO Biotech Aps, Copenhagen, Denmark., Pedersen AW; IO Biotech Aps, Copenhagen, Denmark., Andersen MH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. inge.marie.svane@regionh.dk.
Publikováno v:
Nature medicine [Nat Med] 2021 Dec; Vol. 27 (12), pp. 2212-2223. Date of Electronic Publication: 2021 Dec 09.
Autor:
Kverneland AH; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark., Chamberlain CA; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark., Borch TH; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark., Nielsen M; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark., Mørk SK; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark., Kjeldsen JW; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark., Lorentzen CL; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark., Jørgensen LP; Department of Pathology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark., Riis LB; Department of Pathology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark., Yde CW; Department of Clinical Genetics, Kennedy Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Glostrup, Denmark., Met Ö; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark., Donia M; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark., Svane IM; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark Inge.Marie.Svane@regionh.dk.; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Oct; Vol. 9 (10).
Autor:
Lorentzen CL; University of Copenhagen, Copenhagen, Denmark.; Center for Cancer Immune Therapy (CCIT), Department of Hematology, 65Q9 Copenhagen University Hospital, Herlev, Denmark., Straten PT; Center for Cancer Immune Therapy (CCIT), Department of Hematology, 65Q9 Copenhagen University Hospital, Herlev, Denmark.
Publikováno v:
Scandinavian journal of immunology [Scand J Immunol] 2015 Oct; Vol. 82 (4), pp. 307-19.